509 related articles for article (PubMed ID: 19828011)
21. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
[TBL] [Abstract][Full Text] [Related]
22. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
23. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
[TBL] [Abstract][Full Text] [Related]
24. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
26. Is there a role for immunotherapy in hepatocellular carcinoma?
Zerbini A; Pilli M; Ferrari C; Missale G
Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
28. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
29. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.
Wang M; Li J; Wang L; Chen X; Zhang Z; Yue D; Ping Y; Shi X; Huang L; Zhang T; Yang L; Zhao Y; Ma X; Li D; Fan Z; Zhao L; Tang Z; Zhai W; Zhang B; Zhang Y
Int J Clin Exp Pathol; 2015; 8(4):3513-28. PubMed ID: 26097535
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
31. Locoregional immunochemotherapy in hepatocellular carcinoma.
Kountouras J; Boura P; Kouklakis G
Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
[TBL] [Abstract][Full Text] [Related]
32. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
33. [Immune therapy against hepatocellular carcinoma using gene-modified tumor cells].
Miyagi T; Tatsumi T; Hayashi N
Nihon Rinsho; 2001 Oct; 59 Suppl 6():688-92. PubMed ID: 11762038
[No Abstract] [Full Text] [Related]
34. New therapies for hepatocellular carcinoma.
Avila MA; Berasain C; Sangro B; Prieto J
Oncogene; 2006 Jun; 25(27):3866-84. PubMed ID: 16799628
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of a tumor promotion immune response via induction of oral tolerance towards tumor-associated-antigens: can we 'eat the tumor'?
Gotsman I; Ilan Y
Med Hypotheses; 2001 Apr; 56(4):487-92. PubMed ID: 11339853
[TBL] [Abstract][Full Text] [Related]
36. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection.
Cai MY; Xu YF; Qiu SJ; Ju MJ; Gao Q; Li YW; Zhang BH; Zhou J; Fan J
Clin Cancer Res; 2009 Jul; 15(14):4686-93. PubMed ID: 19584149
[TBL] [Abstract][Full Text] [Related]
37. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
Zhu AX
Oncologist; 2006; 11(7):790-800. PubMed ID: 16880238
[TBL] [Abstract][Full Text] [Related]
38. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
39. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Seifi-Alan M; Shamsi R; Ghafouri-Fard S
Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma (HCC): current and evolving therapies.
Gish RG; Baron A
IDrugs; 2008 Mar; 11(3):198-203. PubMed ID: 18311657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
